{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:42Z","timestamp":1792122222447,"version":"4.4.0"},"reference-count":96,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma (MM) is the second most common hematological malignancy in the US and Europe\u2014comprising approximately 10% of all hematologic cancer cases\u2014and its incidence has increased over the last three decades by approximately 120% due to an aging world population. It remains an incurable cancer among diseases in modern medicine. This review outlines the relevant cancer biology of MM, with a special emphasis on the role of tumor protein p53. We provide the most up-to-date summary of the current drugs in clinical or pre-clinical trials targeting weaknesses in the MM apoptotic mechanism. In addition, we highlight the potential for new routes to strike and kill myeloma cells, possibly creating a vaccine-like effect that prevents relapse, using the principles of immunogenic cell death (ICD).<\/jats:p>","DOI":"10.3390\/ijms27031439","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:00:33Z","timestamp":1770022833000},"page":"1439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-8967","authenticated-orcid":false,"given":"Iulianna","family":"Taritsa","sequence":"first","affiliation":[{"name":"VISKA.Bio, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fossel","sequence":"additional","affiliation":[{"name":"VISKA.Bio, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma","volume":"360","author":"Harousseau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"National Cancer Institute (2025, October 10). Multiple Myeloma. Surveillance, Epidemiology, and End Results Program, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.bbmt.2020.08.018","article-title":"The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study","volume":"26","author":"Cowan","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: A global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bmt.2016.18","article-title":"Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey","volume":"51","author":"Niederwieser","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Paiva","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","article-title":"Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines","volume":"88","author":"Chesi","year":"1996","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1097-2765(00)80180-X","article-title":"Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell","volume":"3","author":"Gabrea","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Facon","year":"2002","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2005.1.346","article-title":"Early genetic events provide the basis for a clinical classification of multiple myeloma","volume":"2005","author":"Kuehl","year":"2005","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma","volume":"20","author":"Chng","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: Clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1200\/JCO.2005.05.023","article-title":"Prognostic and therapeutic significance of myeloma genetics and gene expression profiling","volume":"23","author":"Stewart","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114407","DOI":"10.1016\/j.bcp.2021.114407","article-title":"Regulation of p53 stability as a therapeutic strategy for cancer","volume":"185","author":"Xu","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current Treatment Strategies for Multiple Myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2848","article-title":"Sequencing of myeloma therapy: Finding the right path among many standards","volume":"39","author":"Rajkumar","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ejh.12729","article-title":"The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells","volume":"98","author":"Xu","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.coi.2013.09.003","article-title":"Lineage relationship of effector and memory T cells","volume":"25","author":"Restifo","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chekol Abebe, E., Yibeltal Shiferaw, M., Tadele Admasu, F., and Asmamaw Dejenie, T. (2022). Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.991092"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","article-title":"Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: Case report on POEMS syndrome and multiple myeloma","volume":"11","author":"Xu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-019-0152-y","article-title":"Recent advances on blinatumomab for acute lymphoblastic leukemia","volume":"8","author":"Zhao","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014An emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"Biomark. Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1242\/dmm.006486","article-title":"Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells","volume":"4","author":"Edwards","year":"2011","journal-title":"Dis. Models Mech."},{"key":"ref_60","first-page":"114","article-title":"P53 is required for Doxorubicin-induced apoptosis via the TGF-beta signaling pathway in osteosarcoma-derived cells","volume":"6","author":"Sun","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","article-title":"The multistep nature of cancer","volume":"9","author":"Vogelstein","year":"1993","journal-title":"Trends Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ray, U., and Orlowski, R.Z. (2023). Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040590"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo","volume":"20","author":"Alavi","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e14527","DOI":"10.1200\/JCO.2018.36.15_suppl.e14527","article-title":"HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma","volume":"36","author":"Pahl","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.clml.2019.09.253","article-title":"HDP-101, a Novel BCMA-targeted Antibody Conjugated to \u03b1-Amanitin, is Active against Myeloma with Preferential Efficacy against Pre-clinical Models of Deletion 17p","volume":"19","author":"Singh","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/10428194.2024.2373331","article-title":"Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma","volume":"65","author":"Dimopoulos","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A.C., and Gramignoli, R. (2019). CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies. Cells, 8.","DOI":"10.3390\/cells8121527"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17474086.2024.2353751","article-title":"Elranatamab vs. teclistamab: Battle of the BCMA bispecifics in relapsed\/refractory multiple myeloma","volume":"17","author":"Moore","year":"2024","journal-title":"Expert. Rev. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clml.2024.11.012","article-title":"Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives","volume":"25","author":"Waldschmidt","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: Opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","volume":"43","author":"Vega","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Dietrich","year":"2021","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell\u2013engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population Pharmacokinetics and Exposure\u2013Response with Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: Results From MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: Concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_86","first-page":"A654","article-title":"618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications","volume":"8","author":"Klussman","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jinorgbio.2016.06.021","article-title":"Anticancer metal drugs and immunogenic cell death","volume":"165","author":"Terenzi","year":"2016","journal-title":"J. Inorg. Biochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"25535","DOI":"10.1074\/jbc.M400944200","article-title":"Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Xie, D., Wang, Q., and Wu, G. (2022). Research progress in inducing immunogenic cell death of tumor cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1017400"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41435-021-00161-5","article-title":"Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma","volume":"23","author":"Decraene","year":"2022","journal-title":"Genes Immun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1158\/1538-7445.AM2022-4244","article-title":"Abstract 4244: Using lysosomal immunogenic cell death to target cancer via xanthine oxidase","volume":"82","author":"Taritsa","year":"2022","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41419-022-04912-8","article-title":"The Achilles\u2019 heel of cancer: Targeting tumors via lysosome-induced immunogenic cell death","volume":"13","author":"Iulianna","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"328ra327","DOI":"10.1126\/scitranslmed.aae0105","article-title":"Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma","volume":"8","author":"Garg","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e169240","DOI":"10.1172\/JCI169240","article-title":"Lysosomal lipid peroxidation mediates immunogenic cell death","volume":"133","author":"Phadatare","year":"2023","journal-title":"J. Clin. Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:11:47Z","timestamp":1770181907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031439"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031439","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}